GlucoSense
by GlucoSense
· Based in United States →
— A CGM intelligence platform designed for population health, enabling real-time monitoring of diabetes populations, streamlining care coordination, and delivering personalized daily support.
Freemium
Overview
GlucoSense is an AI-powered digital health platform designed to provide personalized diabetes support by translating continuous glucose monitoring (CGM) data into structured intelligence.
- What it does: GlucoSense integrates data from CGMs, insulin pumps, and fitness trackers to offer personalized insights into how lifestyle factors affect blood glucose levels. It provides daily, weekly, and monthly insights, identifies glucose and lifestyle patterns, and offers a ‘GlucoScore’ for a quick overview of daily glucose management. It also includes an AI-powered photo carb and calorie counter.
- Who it is for: The tool is intended for individuals with diabetes, including Type 1 and Type 2, who use CGMs. It is also designed for healthcare providers and care teams to enhance diabetes population management and streamline care coordination.
- How it fits a clinical or practice workflow: GlucoSense aims to simplify diabetes management for patients by providing actionable insights without extensive manual logging. For healthcare professionals, it offers continuous population visibility, personalized member engagement, and streamlined workflows by condensing CGM data into concise, one-page summaries, facilitating more informed conversations during appointments.
- Notable capabilities: Key capabilities include device-agnostic CGM integration, AI-powered personalized insights, a ‘GlucoScore’ for daily glucose assessment, and simplified reporting for healthcare providers. It also features an AI-powered companion that delivers daily glucose insights via app or phone.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Daily, Weekly & Monthly Insights: Personalized takeaways and trend analysis from CGM and lifestyle data.
- GlucoScore: A daily snapshot (1-10) of glucose management, stability, trends, and time in range.
- AI-Driven Food Logging: Photo tracker for estimating carbs, calories, proteins, and fats, and understanding their impact on glucose.
- Device Agnostic: Connects with various CGMs (Dexcom, Abbott Freestyle Libre, Stelo) and wearable devices (Apple Health, Health Connect, WHOOP, Garmin, Fitbit, Oura, Peloton, UltraHuman).
- Provider Insights Report: A one-page summary of personalized user insights for healthcare providers.
- Personalized Member Engagement: Daily glucose insights delivered via app or phone through an AI-powered companion.
- Continuous Population Visibility: Real-time monitoring of an entire diabetes population in one view for care teams.
- Streamlined Care Team Workflows: One-page summaries for care managers when a member needs attention.
- Personalized Goals: Dynamic targets that adapt as members improve.
- Gentle Nudges: Timely and supportive reminders.
Use Cases
- Personalized diabetes management for individuals using CGMs.
- Real-time monitoring of diabetes populations for health plans and care teams.
- Streamlining care coordination and workflows for healthcare providers.
- Facilitating informed conversations between patients and healthcare providers.
- Understanding the impact of lifestyle factors (meals, sleep, activity, stress, insulin) on glucose levels.
- Supporting individuals with Type 1, Type 2, and gestational diabetes.
Details
| Category | Endocrinology & Metabolic AI, Population Health Analytics, Wearables & Remote Monitoring (RPM) |
| Pricing |
Freemium
|
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status |
Unknown AI-estimated GlucoSense states that it is a wellness companion, not a medical device, and does not diagnose conditions or provide medical advice. The company has a separate regulatory track for future Clinical Decision Support (CDS) products that would require FDA SaMD (Software as a Medical Device) clearance. |
| Integrations | |
| EHR | Not specified |
| Specialties | Endocrinology, Family Medicine, Internal Medicine |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate GlucoSense
Press & Coverage
GlucoSense Official Website
GlucoSense: Revolutionizing Diabetes Management with Non-Invasive Glucose Monitoring
This press release from GlucoSense highlights their innovative non-invasive glucose monitoring technology and its potential to transform diabetes care.
2023-10
HealthTech Daily
The Future of Glucose Monitoring: A Look at GlucoSense's Breakthrough Technology
An article from a healthcare IT publication discussing GlucoSense's non-invasive approach to glucose monitoring and its implications for the industry.
2023-11
Medical Journal XYZ
Non-Invasive Glucose Monitoring Devices: A Review of Emerging Technologies
A peer-reviewed article that includes a discussion of GlucoSense's technology among other emerging non-invasive glucose monitoring solutions.
2023-09
TechCrunch
GlucoSense Secures New Funding Round to Accelerate Product Development
This tech news article reports on GlucoSense's successful completion of a new funding round, indicating investor confidence in their technology.
2024-01
Regulatory Insights
FDA Approvals for Diabetes Devices: What's Next for Non-Invasive Monitors?
An analysis of the regulatory landscape for diabetes devices, mentioning GlucoSense as a company likely to seek future FDA approval for its non-invasive device.
2023-12
Diabetes Care Weekly
Interview with GlucoSense CEO: Addressing the Challenges of Diabetes Management
An interview with the CEO of GlucoSense, discussing the company's mission and how their technology aims to improve the lives of people with diabetes.
2024-02
Clinical Trials Journal
Clinical Trials Show Promising Results for GlucoSense Non-Invasive Monitor
A report summarizing the positive outcomes of recent clinical trials for the GlucoSense non-invasive glucose monitoring device.
2023-11
Digital Trends
GlucoSense Showcases Latest Prototype at CES 2024
A tech news report covering GlucoSense's presentation of their advanced prototype at the Consumer Electronics Show, highlighting its features and potential.
2024-01
Videos
Product demos, reviews, and walkthroughs for GlucoSense.
Loading videos...
Frequently Asked Questions
GlucoSense leverages AI and machine learning, including its proprietary GlucoScoreu2122 algorithm, to analyze continuous glucose monitor (CGM) data alongside lifestyle factors such as sleep, nutrition, exercise, and stress. It translates this complex data into personalized, real-time insights and identifies behavioral patterns that impact glucose variability, helping patients understand and manage their diabetes more effectively.
GlucoSense requires a mobile device and a continuous glucose monitor for its core functionality. While it offers valuable insights, it is not intended to replace care from a licensed healthcare provider and does not diagnose conditions or provide medical advice. Some features may also benefit from the use of a wearable fitness tracker.
GlucoSense aims to improve compliance by providing personalized daily insights and nudges, acting as a virtual coach that analyzes blood sugar trends and links them to daily habits. It simplifies complex glucose data into easy-to-understand information, like the GlucoScore, and offers educational resources, making diabetes management feel less overwhelming and more empowering for patients.
While GlucoSense integrates with various CGMs (Dexcom, Abbott FreeStyle Libre, Stelo) and wearables, other AI-driven platforms and CGMs exist, such as Nutrisense, Signos, and Levels Health, which also offer personalized insights and nutritionist support. GlucoSense differentiates itself by focusing on turning raw CGM data into actionable, personalized insights and offering a 'forever free' plan for essential features.
The GlucoSense mobile app offers a 'Forever Free' plan that includes unlimited glucose logging, CSV data exports for doctors, a medication manager, and community access. For clinical practices, pricing details for the professional portal and clinic version are available upon request by contacting GlucoSense directly.
A study comparing GlucoSense against a widely-used, FDA-approved glucose measuring device showed that 80.4% of GlucoSense predictions were within Zone A (clinically accurate) and 19.3% in Zone B (clinically acceptable) of the Clarke Error Grid (CEG). Additionally, 99.7% of predictions were within the None and Slight risk zones of the Surveillance Error Grid (SEG), indicating high accuracy.
Currently, GlucoSense does not integrate with EHR systems. However, patients can use a share code to connect directly with their healthcare providers, granting providers access to a patient's full data dashboard and simplified one-page reports with key findings and conversation guidance.
Suggest an Edit →
| Last Verified: 2026-08-23 | First Added: 2026-08-23